Company: RNAC
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001453687-25-000120
Chunk: 97

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part II, Item 6
Chunk 97
---
Item 6. Exhibits

EXHIBIT INDEX

  Incorporated by ReferenceExhibitNumberExhibit DescriptionFormFile No.ExhibitFilingDate2.1*Agreement and Plan of Merger, dated November 13, 2023, by and among Selecta Biosciences, Inc., Sakura Merger Sub I, Inc., Sakura Merger Sub II, LLC, and Cartesian Therapeutics, Inc.8-K001-377982.111/13/20233.1(a)Restated Certificate of Incorporation of Selecta Biosciences, Inc.8-K001-377983.16/29/20163.1(b)Certificate of Amendment to the Restated Certificate of Incorporation of Selecta Biosciences, Inc., dated June 21, 20228-K001-377983.16/21/20223.1(c)Certificate of Amendment to the Restated Certificate of Incorporation of Selecta Biosciences, Inc., dated November 13, 20238-K001-377983.311/13/20233.1(d)Certificate of Amendment to the Restated Certificate of Incorporation, as amended, of Cartesian Therapeutics, Inc., dated March 28, 2024.8-K001-377983.23/28/20243.2Amended and Restated By-laws of Cartesian Therapeutics, Inc.8-K001-377983.210/30/20254.1(a)Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock8-K001-377983.411/13/20234.1(b)Certificate of Amendment to the Certificate of Designation of Series A Non-Voting Convertible Preferred Stock, dated March 26, 2024.8-K001-377983.13/28/20244.2Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock8-K001-377983.17/2/202431.1Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002---Filed herewith31.2Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)